Physician profile
Emad Ali
NPI 1104251453
$2,554.90
in general payments reported to CMS, 2019-2025
16 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.51 · 2020: $34.44 · 2023: $857 · 2024: $1,102 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576 · Travel and Lodging: $857 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.31 |
| Travel and Lodging | $857.14 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,223.35 | 2023-2025 | Minimed 780g, Minimed 770g |
| Abbott Laboratories | $299.17 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $201.91 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $153.22 | 2023-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $152.87 | 2024 | |
| Amgen INC. | $107.23 | 2019-2025 | Evenity, Tepezza, Prolia |
| Insulet Corporation | $97.16 | 2023-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $87.82 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $57.96 | 2025 | Korlym |
| Pfizer INC. | $44.78 | 2019-2020 | |
| Mannkind Corporation | $42.50 | 2025 | |
| Globus Medical, INC. | $24.67 | 2025 | Senza |
| Astrazeneca Pharmaceuticals Lp | $19.13 | 2020 | |
| Xeris Pharmaceuticals, INC. | $15.91 | 2023 | Gvoke Hypopen |
| Madrigal Pharmaceuticals | $13.74 | 2025 | Rezdiffra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $13.48 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.